Loading
DiaMedica Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 08 Dec 2025.
DiaMedica Therapeutics Inc.: what insiders have been doing
Every trade that managers of DiaMedica Therapeutics Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 16 filings signed by 14 insiders.
The flow runs one way only: 1 insider bought (1 purchase totalling €1.1M) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €1.1M from Stahlberg Jan, disclosed on 8 December 2025.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 16 filings, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 29 purchases and 1 sale.
The last insider purchase was made public on 8 December 2025, 314 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
65
Thresholds
n/a
Buy Volume
€29M
29 ops. · all time
Sell Volume
€3M
1 ops. · all time
Who traded when
BuySaleJan Stahlberg3 buys
Richard Jacinto II1 buy
Thomas Von Koch1 buy
Since the insiders bought
- -14.1%Entry US$9.07 · Close at T+90 US$7.79
- +33.2%Entry US$5.06 · Close at T+365 US$6.74
- +33.2%Entry US$5.06 · Close at T+365 US$6.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.04
Analyst consensus
4 analysts1.00/5
US$11.00Target US$15.50(+93%)US$25.00
Income statement
RevenueUS$430.5k
EBITDA-US$34.4M-7980% margin
Net income-US$32.8M0.0% margin
Valuation
PER (forward)-10.0x
P/Book11.3x
Beta0.91
Balance sheet & cash
Market capUS$433.6M
Total debtUS$240k
Free Cash Flow-US$29.1M
Debt / Equity0%
Profitability & ownership
ROE-114.6%
ROA-64.1%
% insiders27.8%
% institutions40.9%
Last declaration on 12 August 2026
Declarations65 total
60,200 shares0Voting Common Shares, no par value per shareSEC:0001760123-26-000004:0
67,500 sharesOptionsTSXSEDI:4762142
67,500 sharesOptionsTSXSEDI:4728899
162,000 sharesOptionsTSXSEDI:4728894
40,412 sharesOptionsTSXSEDI:4728882
40,412 sharesOptionsTSXSEDI:4728872
40,412 sharesOptionsTSXSEDI:4728863
40,412 sharesOptionsTSXSEDI:4728857
40,412 sharesOptionsTSXSEDI:4728855
51,189 sharesOptionsTSXSEDI:4728850
380,000 sharesOptionsTSXSEDI:4728846
3,355 shares@ US$8.4216.5% of flowCommon StockSEC:0001872863-26-000002:0
10,095 shares@ US$8.4225.4% of flowCommon StockSEC:0001759855-26-000002:0
6,175 shares@ US$8.428.0% of flowCommon StockSEC:0001759822-26-000002:0
187,393 shares@ US$6.516610.6% of flowCommon SharesSEC:0001104659-25-119360:0
Canonical exit: 15 Feb 2026 (T+90)
12,000 shares@ US$2.208.0% of flowCommon StockSEC:0001759855-25-000006:0
293,601 shares@ US$5.909114.9% of flowCommon SharesSEC:0001104659-25-087410:0
Canonical exit: 11 Nov 2025 (T+90)
1,542,857 shares@ US$3.5046.2% of flowCommon SharesSEC:0001104659-25-070920:0
Canonical exit: 21 Oct 2025 (T+90)
2,857,142 shares@ US$3.5043.6% of flowCommon SharesSEC:0001104659-25-070900:0
Canonical exit: 21 Oct 2025 (T+90)
400,000 shares@ US$3.50100.0% of flowVoting Common Shares, no par value per shareSEC:0001437749-25-023532:0
Canonical exit: 21 Oct 2025 (T+90)
24,000 shares@ US$2.118.9% of flowVoting Common Shares, no par value per shareSEC:0001760016-25-000004:0
12,000 shares@ US$2.114.4% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000009:0
5,290 shares@ US$5.3418.8% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000001:0
10,393 shares@ US$5.3410.3% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000002:0
15,917 shares@ US$5.3428.9% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000005:0
25 of 65 declarations
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the ticker DMAC in the United States. For French-, Belgian- and Swiss-based investors, it is best understood as a development-stage biotech with a concentrated asset profile rather than a diversified commercial pharmaceutical company. The company’s strategy is focused on vascular diseases driven by impaired blood flow and endothelial dysfunction, with current clinical emphasis on preeclampsia, fetal growth restriction, and acute ischemic stroke. ([diamedica.com](https://www.diamedica.com/investors))
DiaMedica has a longer corporate history than its present market profile might suggest. The business traces back to 2000, and its current identity was shaped through corporate restructuring and a name change in 2016. Its headquarters are in Minneapolis, Minnesota, placing it in a well-established U.S. life-sciences hub. In market terms, DMAC remains a small-cap clinical biotech whose valuation case is tied to pipeline execution, clinical readouts, and continued access to capital markets to fund development. ([diamedica.com](https://www.diamedica.com/investors/financial-reports/sec-filings/content/0001437749-25-009703/0001437749-25-009703.pdf))
Read moreShow less
The company’s lead program is DM199, a recombinant form of human tissue kallikrein-1 (rhKLK1). DiaMedica describes DM199 as the first pharmaceutically active recombinant version of KLK1, designed to restore vascular function and improve blood flow while potentially reducing inflammation and oxidative stress. In preeclampsia and fetal growth restriction, the goal is to address the underlying pathophysiology rather than only symptoms. In acute ischemic stroke, the rationale is to enhance collateral perfusion and potentially broaden the treatment opportunity relative to current care pathways. ([diamedica.com](https://www.diamedica.com/company?utm_source=openai))
From a competitive standpoint, DiaMedica operates in a specialized but crowded biotech landscape. Its differentiation comes from the KLK1 biology and from the fact that kallikrein-based therapeutic concepts have historical precedent in Asia for vascular indications. That said, the company does not yet have a commercial product portfolio, so the investment thesis is highly binary and depends primarily on the quality of clinical evidence, enrollment progress, and regulatory traction. As with many clinical-stage names, the principal risks remain trial success, financing needs, and dilution. ([diamedica.com](https://www.diamedica.com/investors/press-releases/detail/1723/diamedica-therapeutics-reports-full-year-2025-financial))
Recent company updates reinforce that clinical development remains the central value driver. In 2025 DiaMedica disclosed interim Phase 2 preeclampsia results, and in 2026 it has continued to publish business updates and financial results, including commentary that the ReMEDy2 trial is continuing to enroll and expand globally. The company has also been active on the conference circuit in 2026, which is consistent with a small-cap biotech seeking broader institutional awareness. For investors monitoring SEC Form 4 insider transactions, DMAC should therefore be viewed as a research-driven Nasdaq issuer in the United States where insider activity, clinical milestones, and trial data can all have material impact on sentiment. ([diamedica.com](https://www.diamedica.com/))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
